Defining conversion therapy for esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Defining conversion therapy for esophageal squamous cell carcinoma

Published:2022-10-19 Issue:1 Volume:7 Page:7-9
ISSN:2475-0328
Container-title:Annals of Gastroenterological Surgery
language:en
Short-container-title:Annals of Gastroent Surgery

Author:

Matsuda Satoru¹^ORCID,Tsushima Takahiro²,Kato Ken³,Hsu Chih‐Hung⁴,Lee Jang Ming⁵^ORCID,Wong Ian Yu‐Hong⁶,Wang Hu‐Lin Christina⁷,Kang Chang Hyun⁸,Guo Xufeng⁹,Yamamoto Shun³,Tsuji Takayuki¹,Kawakubo Hirofumi¹^ORCID,Takeuchi Hiroya¹⁰,Law Simon⁶,Kitagawa Yuko¹

Affiliation:

1. Deepartment of Surgery Keio University School of Medicine Tokyo Japan

2. Division of Gastrointestinal Oncology Shizuoka Cancer Center Shizuoka Japan

3. Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital Tokyo Japan

4. Division of Medical Oncology, Department of Oncology National Taiwan University Hospital Taipei Taiwan

5. Department of Surgery National Taiwan University Hospital Taipei Taiwan

6. Department of Surgery, School of Clinical Medicine The University of Hong Kong Hong Kong China

7. Division of Traumatology Far Eastern Memorial Hospital Taipei Taiwan

8. Department of Thoracic and Cardiovascular Surgery Seoul National University Hospital Seoul Korea

9. Department of Thoracic Surgery, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

10. Department of Surgery Hamamatsu University School of Medicine Hamamatsu Japan

Publisher

Wiley

Subject

Gastroenterology,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ags3.12623

Reference5 articles.

1. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

2. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

3. International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)

4. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

5. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study;Annals of Surgical Oncology;2024-09-12

2. Esophagectomy in patients with esophageal squamous cell carcinoma and distant nodal metastasis;Diseases of the Esophagus;2024-08-16

3. Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review;Journal of Neuroendocrinology;2024-06-27

4. Can Immune Checkpoint Inhibitors Pave the New Way for “Conversion Surgery” in Unresectable Esophageal Cancer?;Annals of Surgical Oncology;2024-06-10

5. The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study;International Journal of Clinical Oncology;2024-04-28